https://scholars.lib.ntu.edu.tw/handle/123456789/470805
標題: | β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma | 作者: | LI-CHUN LU YU-YUN SHAO Lee Y.-H. MIN-SHU HSIEH Hsiao C.-H. Lin H.-H. HSIANG-FONG KAO Ma Y.-Y. Yen F.-C. ANN-LII CHENG CHIH-HUNG HSU |
公開日期: | 2014 | 出版社: | S. Karger AG | 卷: | 87 | 期: | 3 | 起(迄)頁: | 159-166 | 來源出版物: | Oncology (Switzerland) | 摘要: | Objectives: Mutation of the exon 3 of CTNNB1, the coding gene of β-catenin, is a crucial molecular mechanism leading to aberrant activation of the Wnt/β-catenin pathway, which is highly associated with the carcinogenesis of hepatocellular carcinoma (HCC). The prevalence and clinical significance of CTNNB1 mutations in advanced HCC remain unclear. Methods: Patients with advanced HCC and available pathologic tissues (either obtained when diagnosed at advanced or early stages) were enrolled in this study. Direct sequencing of exon 3 of CTNNB1 was performed to detect somatic mutations. The associations between CTNNB1 mutations and clinicopathologic features were analyzed. Results: A total of 115 patients were enrolled, among whom 78 (67.8%) had chronic hepatitis B virus infection. Twenty-one (18.3%) patients were found to have CTNNB1 mutations, all of which were missense mutations. The CTNNB1 mutation rates were similar among pathologic tissues obtained at advanced and early stages (17.5 and 20.0%, respectively). Patients aged over 60 years were more likely to have CTNNB1 mutations than patients younger than 60 years (32.6 vs. 8.7%, p = 0.001). The mutations were not associated with survival or other clinicopathologic features. Conclusion: In patients with advanced HCC, CTNNB1 mutations were not prognostically significant. No apparent increase of CTNNB1 mutations occurred during the progression of HCC. ? 2014 S. Karger AG, Basel. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903858986&doi=10.1159%2f000362821&partnerID=40&md5=83f25d8bc25cddf06bccd01f63d40e96 https://scholars.lib.ntu.edu.tw/handle/123456789/470805 |
ISSN: | 0030-2414 | DOI: | 10.1159/000362821 | SDG/關鍵字: | alpha fetoprotein; angiogenesis inhibitor; beta catenin; sorafenib; adult; advanced cancer; article; bone metastasis; cancer prognosis; cancer staging; cancer survival; clinical trial (topic); exon; female; gene mutation; genetic association; hepatitis B; hepatitis C; human; human tissue; liver cell carcinoma; lung metastasis; major clinical study; male; medical record review; missense mutation; overall survival; priority journal; somatic mutation; advanced cancer; Article; beta catenin gene; cancer prognosis; chronic hepatitis B; clinical feature; gene; gene sequence; liver cell carcinoma; Adult; Aged; Aged, 80 and over; beta Catenin; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Survival Rate; Tumor Markers, Biological; Young Adult |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。